custom image

Asthma: New Discoveries and Therapies in the Age of COVID

December 1-2, 2020 | 10:00AM EST | 3:00PM UTC* 
*Program is in development subject to change

Asthma and related diseases in the form of COPD and asthma-COPD are a remarkably common, affecting over 50 million patients in the US alone. Moreover, this disease spectrum overlaps with inflammatory lung disease driven by respiratory viral infection, including COVID-19. In the case of asthma, the pathology is thought to arise from an aberrant type 2 immune response, but the cellular and molecular mechanisms of this response require more precise definition, including any contribution from non-type 2 immune mechanisms. Clinical trials based on these concepts have revealed both successes and also some unforeseen failures that need to be addressed and included in the framework of respiratory viruses in general and SARS-CoV-2 in particular. This Keystone Symposia conference on asthma will highlight the most recent basic science breakthroughs in the pathogenesis of asthma and related inflammatory airway diseases and focus on the development of new therapeutics for asthma and related progressive respiratory disease. In addition, the program will review these discoveries in the context of new therapeutic directions, including the context of emerging information about COVID-19. The program has been designed to emphasize to identify, validate, and translate new disease targets into new therapeutics. The topic is timely and urgent given the recent mechanistic insights into inflammatory airway disease, the current maturation of new biological therapies for this type of disease, and the overlap of this information with progressive lung disease after respiratory viral infections, including COVID-19.


Registration for this meeting is now closed.


Abstract Submission
for Short Talk Consideration:
ePoster Abstract Submission: Passed
Financial Aid Application: Passed


Program Details

Speaking at this eSymposia

Karen Affleck

GlaxoSmithKline, UK

Rafeul Alam

National Jewish Health, USA

Joseph R. Arron

Genentech Inc., USA

Nora A. Barrett

Brigham and Women's Hospital, USA

Maria Belvisi

Imperial College London / AstraZeneca, UK

Jonathan Corren

University of California, Los Angeles, USA

David B. Corry

Baylor College of Medicine, USA

Jeffrey Haspel

Washington University in St. Louis, USA

Michael J. Holtzman

Washington University in St. Louis, USA

Elliot Israel

Harvard Medical School/Brigham & Women's Hospital, USA

Vijay K. Kuchroo

Brigham and Women's Hospital, Harvard Medical School, USA

Bart N. Lambrecht

VIB, Ghent University, Belgium

Clare M. Lloyd

Imperial College London, UK

Parameswaran Nair

McMaster University, Canada

Martijn C. Nawijn

University Medical Center Groningen, Netherlands

Bali Pulendran

Stanford University School of Medicine, USA

Anuradha Ray

University of Pittsburgh School of Medicine, USA

Alexander Scheffold

Christian-Albrechts-Universität zu Kiel, Germany

Anne I. Sperling

University of Chicago, USA

Jenny P.Y. Ting

University of North Carolina at Chapel Hill, USA

Prescott G. Woodruff

University of California, San Francisco, USA





Additional Support




Funding for this conference was made possible (in part) by Grant No. 1 R13 HL152474-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Media-in-Kind Support





The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.

Related Keystone Symposia In-Person Meetings

Explore all cancer-related meetings on the Keystone Symposia website.

custom image

custom image

custom image

Donate to Keystone Symposia

custom image